Palisade Bio's PALI-2108 Shows Rapid Ulcerative Colitis Response in Phase 1b Data

Event summary

  • Palisade Bio presented Phase 1b data for PALI-2108 at ECCO 2026, showing 100% clinical response in moderate-to-severe ulcerative colitis patients within seven days.
  • RNA sequencing data demonstrated localized suppression of inflammatory and fibrotic gene programs in colon tissue with minimal peripheral immune modulation.
  • PALI-2108 showed a favorable safety profile across 89 subjects with no serious adverse events reported.
  • The company plans to advance PALI-2108 into a Phase 2 clinical study in ulcerative colitis and complete early studies in fibrostenotic Crohn’s disease.

The big picture

Palisade Bio's Phase 1b data for PALI-2108 underscores the potential of targeted PDE4 inhibition in ulcerative colitis, a market with significant unmet needs. The localized approach aims to address tolerability issues associated with systemic PDE4 inhibitors, positioning PALI-2108 as a potential differentiator in the inflammatory bowel disease space. The company's strategy of leveraging bacterial bioactivation for targeted drug delivery could set a new standard for treating gastrointestinal inflammation.

What we're watching

Clinical Validation
Whether the rapid clinical response observed in the Phase 1b trial will be replicated in larger, later-stage studies.
Regulatory Pathway
The pace at which Palisade Bio can advance PALI-2108 through Phase 2 trials and potentially secure regulatory approval.
Market Differentiation
How PALI-2108's targeted colon delivery mechanism will position it against existing and emerging therapies for ulcerative colitis.